Tools
Stock profile

QUEST DIAGNOSTICS INC (DGX)

DGX · Latest close $259.69 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$259.69
As of Nov 18, 2026
Tracked funds holding
3 of 149
2026 Q2 13F filings
Opened / added
0 / 2
vs previous quarter
Trimmed / exited
3
vs previous quarter

QUEST DIAGNOSTICS INC (DGX) is held by 3 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 2 funds adding and 3 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $19.8M sold). Latest close $259.69 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 13, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-19.8M
Fundamentals
Revenue · FY2025
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

EdgePoint Investment Group · Davis Advisors · First Eagle Investment Management — 3 tracked funds hold DGX. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 17 sales ($19.8M). Insider trading

Often held alongside

Natera, Inc. (NTRA) · Guardant Health, Inc. (GH) · LABCORP HOLDINGS INC. (LH) · RadNet, Inc. (RDNT) · EXAGEN INC. (XGN) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
EdgePoint Investment Group3.60%2,247,568ADDED (+0.2%) Q3 filed Nov 16
Davis Advisors1.42%1,555,612TRIMMED (-3.8%) Q3 filed Nov 10
First Eagle Investment Management<0.01%7,606ADDED (+153.5%) Q3 filed Nov 10
Maverick Capital——EXITED
Check Capital Management——EXITED

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +18.7% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

262.21145.852024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding1,107 of 8,857 filers
Long-only filers among them1,104
Change vs 2026 Q1+54 net · 970 entered · 916 exited
Shares reported, all filers104,363,698
Reported value, all filers$20.5B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNYSE
IndustryServices-Medical Laboratories (SIC 8071)
Revenue · FY2025$11.0B
Net income · FY2025$992.0M
Total assets · FY2025$16.2B
Shares outstanding110,019,073
Market cap (at latest close)$28.6B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Oct 15, 2026.

Short interest

Shares short · Oct 15, 20263,573,902
Share of shares outstanding3.25%
Days to cover3.38

Shares short at recent settlements — Jul 31, 2026: 3.7M · Aug 14, 2026: 3.3M · Aug 31, 2026: 3.4M · Sep 15, 2026: 3.6M · Sep 30, 2026: 3.4M · Oct 15, 2026: 3.6M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Oct 15, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Oct 15, 2026.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 17 sales by 6 insiders ($19.8M).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Nov 13, 2026Deppe Michael JSVP, Corp. Controller & CAOSell6,261$260.17$1.6MSEC filing
Nov 13, 2026Deppe Michael JSVP, Corp. Controller & CAOSell5,515$260.17$1.4MSEC filing
Nov 9, 2026Plewman PatrickSVP for Diagnostic ServicesSell4,274$257.34$1.1MSEC filing
Nov 9, 2026Plewman PatrickSVP for Diagnostic ServicesSell6,793$257.34$1.7MSEC filing
Nov 9, 2026Plewman PatrickSVP for Diagnostic ServicesSell650$257.34$167.3KSEC filing
Nov 3, 2026Doherty Catherine T.Executive Vice PresidentSell3,818$245.45$937.1KSEC filing
Nov 3, 2026Doherty Catherine T.Executive Vice PresidentSell5,990$246.26$1.5MSEC filing
Nov 3, 2026Doherty Catherine T.Executive Vice PresidentSell1,151$246.98$284.3KSEC filing
Nov 3, 2026Doherty Catherine T.Executive Vice PresidentSell2,358$248.38$585.7KSEC filing
Nov 3, 2026Doherty Catherine T.Executive Vice PresidentSell3,004$249.40$749.2KSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Sep 1, 2026Davis J. E.Officer, Director10,000$2.4MSep 1, 2026SEC filing
Aug 28, 2026PREVOZNIK MICHAEL EOfficer22,677$5.5MAug 28, 2026SEC filing
Jul 28, 2026DELANEY MARK EOfficer1,600$376.3KJul 28, 2026SEC filing
Jun 4, 2026KUPPUSAMY KARTHIKOfficer8,147$1.6MJun 4, 2026SEC filing
Jun 1, 2026Davis J. E.Officer, Director10,000$1.9MJun 1, 2026SEC filing
Mar 5, 2026PREVOZNIK MICHAEL EOfficer3,878$799.7KMar 5, 2026SEC filing
Mar 5, 2026Doherty Catherine T.Officer5,558$1.1MMar 5, 2026SEC filing
Mar 5, 2026Plewman PatrickOfficer2,855$588.7KMar 5, 2026SEC filing
Mar 3, 2026Doherty Catherine T.Officer632$131.3KMar 3, 2026SEC filing
Mar 3, 2026PREVOZNIK MICHAEL EOfficer526$109.3KMar 3, 2026SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Aug 14, 2026T. Rowe Price Associates, Inc.SC 13G/A5,428,2444.9%Jun 30, 2026SEC filing
Apr 30, 2026Vanguard Capital ManagementSC 13G8,274,5677.5%Mar 31, 2026SEC filing
Apr 29, 2026Vanguard Portfolio ManagementSC 13G6,096,6295.5%Mar 31, 2026SEC filing
Mar 27, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Aug 14, 2025T. Rowe Price Associates, Inc.SC 13G/A7,209,6226.5%Jun 30, 2025SEC filing
May 14, 2025T. Rowe Price Associates, Inc.SC 13G5,995,3355.4%Mar 31, 2025SEC filing
Apr 17, 2025BlackRock, Inc.SC 13G/A9,308,8158.4%Mar 31, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Services-Medical Laboratories (SIC 8071). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 263 Lobbying Disclosure Act filings named this company as client, 1999–2026; most common issues: Health Issues (226), Medicare/Medicaid (191), Budget/Appropriations (20).

Federal contracts: $734.6M in obligated amounts, fiscal years 2021–2026.

Fiscal yearObligated amount
FY2021$163.4M
FY2022$212.4M
FY2023$138.0M
FY2024$100.9M
FY2025$49.9M
FY2026$70.0M

Largest awards collected

Award IDAgencyAmountStart
VA24716F1843Department of Veterans Affairs$43.8MJul 1, 2016
75D30122C13699Department of Health and Human Services$27.1MMay 16, 2022
75D30121C10058Department of Health and Human Services$22.8MNov 13, 2020
75D30120F00001Department of Health and Human Services$12.3MJul 30, 2020
75P00121P00008Department of Health and Human Services$11.0MMay 6, 2020

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Financial Screens

· Dividend Growth — Dividends raised for more than 10 years

· Earnings Quality (Cash Conversion) — Profits that actually come back as cash

· Earnings Stability — Small earnings swings and almost no loss years

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

· 52-Week High — Recently printed a new 52-week high

· Top Relative Strength — Top 20% of the universe by 6-month return

Key figures

· Dividend Growth — Dividend per share: 1.80 · Dividend yield: 0.7% · Straight dividend years: 11 · 10-yr dividend growth: 350.0%

· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 1.64 · Operating cash flow: $1.9B · Net income: $992.0M

· Earnings Stability — Earnings variation (CV): 0.38 · Loss years (of 10): 0 · Latest net income: $992.0M

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

13F signal (2021 Q3 – 2026 Q1)EventsWin rateAvg returnSPYExcess
Heavy accumulation — 3+ tracked funds increased together1100.0%+5.8%-6.9%+12.7%

Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.

Also held by the tracked funds that hold DGX — ranked by lift, the co-holding pattern described in Methodology: Natera, Inc. (NTRA) · Guardant Health, Inc. (GH) · LABCORP HOLDINGS INC. (LH) · RadNet, Inc. (RDNT) · EXAGEN INC. (XGN) · BillionToOne, Inc. (BLLN) · CareDx, Inc. (CDNA) · HCA Healthcare, Inc. (HCA).

8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.

Recent 8-K filings

FiledItemsSource
Oct 22, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Oct 22, 20268.01 Other EventsSEC filing
Oct 6, 20265.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain OfficersSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

Natera, Inc. (NTRA) · Track Record: how the signals scored · Practice timing on DGX

One email a week: the week’s new filings and research. Subscribe free

← DGII  ·  DHC →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.